Morgan Stanley has increased its price target on Moderna by 77% this week. Shares of the company have been soaring as a result. Analyst Matthew Harrison however still won’t recommend buying Moderna shares, and cut his ratings on Dow components Johnson & Johnson, Merck and Amgen The stock has rallied 17.7% over the past five … Continue reading “Moderna Shares Rise as Morgan Stanley Boosts Price Target”
